The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial

Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study)

(2016) V. R. Aroda et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial

(2016) H. W. Rodbard et al.   DIABETIC MEDICINE

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes

(2016) Ildiko Lingvay et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial

(2016) Yutaka Seino et al.   Journal of Diabetes Investigation

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial

(2015) S. C. L. Gough et al.   DIABETES OBESITY & METABOLISM

Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?

(2015) Richard Simpson et al.   Expert Review of Clinical Pharmacology

AACE Comprehensive Diabetes Management Algorithm 2013

(2015) Alan Garber et al.   Endocrine Practice

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)

(2014) John B. Buse et al.   DIABETES CARE

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)

(2014) C. Mathieu et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

(2014) Stephen C L Gough et al.   Lancet Diabetes & Endocrinology

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists

(2013) Dara L. Eckerle Mize et al.   Current Diabetes Reports

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine

(2013) Matthew C. Riddle et al.   DIABETES CARE

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents

(2013) A. Philis-Tsimikas et al.   DIABETES OBESITY & METABOLISM

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

(2013) H. W. Rodbard et al.   DIABETIC MEDICINE

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

(2012) J. H. DeVries et al.   DIABETES CARE

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability

(2011) A. J. Garber   DIABETES CARE

Examining the ability to detect change using the TRIM-Diabetes and TRIM-Diabetes Device measures

(2011) Meryl Brod et al.   QUALITY OF LIFE RESEARCH

Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes

(2010) S. G. Swinnen et al.   DIABETES OBESITY & METABOLISM

Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device)

(2009) Meryl Brod et al.   Health and Quality of Life Outcomes

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE